Clearmind Medicine to Present Phase I/IIa CMND-100 Trial Data in June 10 Webinar
Clearmind Medicine will host a one-hour webinar on June 10, 2026, presenting Phase I/IIa data from its ongoing CMND-100 trial for Alcohol Use Disorder and featuring Yale and Johns Hopkins investigators. The online session will review positive safety signals and discuss MEAI’s non-hallucinogenic neuroplastogenic mechanism for treating Alcohol Use Disorder.
1. Upcoming Webinar on CMND-100 Trial Insights
Clearmind Medicine will host a one-hour webinar on Wednesday, June 10, 2026, from 4:00 PM to 5:00 PM IDT to present Phase I/IIa data from its ongoing CMND-100 trial targeting Alcohol Use Disorder. Investors and researchers can register online to secure access to this detailed clinical update.
2. Clinical Data Focus and Safety Signals
The webinar will review positive safety signals and encouraging early efficacy observations from the FDA-approved, multi-center trial of MEAI-based oral drug candidate. Discussion will center on MEAI’s non-hallucinogenic neuroplastogenic mechanism and its potential to address major unmet needs in alcohol addiction treatment.
3. Presenters and Discussion Topics
Featured speakers include Dr. Anahita Bassir Nia, an addiction psychiatrist at Yale School of Medicine, and Dr. Jennifer Ellis, a clinical psychologist at Johns Hopkins Medicine. Company CEO Dr. Adi Zuloff-Shani will moderate the live Q&A and outline future clinical development strategies.